Correction to: Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel

Correction to: Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel

The original article contains several small errors. The errors & concurrent corrections are listed below [1]:

Bibliographic Details
Main Authors:	D. Porter, N. Frey, P. A. Wood, Y. Weng, S. A. Grupp
Format:	Article
Language:	English
Published:	BMC 2018-06-01
Series:	Journal of Hematology & Oncology
Online Access:	http://link.springer.com/article/10.1186/s13045-018-0627-z

Similar Items

Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel
by: David Porter, et al.
Published: (2018-03-01)

Kymriah® (tisagenlecleucel) – An overview of the clinical development journey of the first approved CAR-T therapy
by: Rakesh Awasthi, et al.
Published: (2023-01-01)

CTL019 (tisagenlecleucel): CAR-T therapy for relapsed and refractory B-cell acute lymphoblastic leukemia
by: Vairy S, et al.
Published: (2018-11-01)

Cytokine release syndrome: grading, modeling, and new therapy
by: Delong Liu, et al.
Published: (2018-09-01)

Interleukin Inhibitors in Cytokine Release Syndrome and Neurotoxicity Secondary to CAR-T Therapy
by: Puri Ferreros, et al.
Published: (2022-07-01)

Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy
by: Zhenguang Wang, et al.
Published: (2018-01-01)

Tisagenlecleucel Model‐Based Cellular Kinetic Analysis of Chimeric Antigen Receptor–T Cells
by: Andrew M. Stein, et al.
Published: (2019-05-01)

Case Report: Cardiac Tamponade in Association With Cytokine Release Syndrome Following CAR-T Cell Therapy
by: Shohei Moriyama, et al.
Published: (2022-03-01)

Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies
by: Xinyi Xiao, et al.
Published: (2021-11-01)

Assessment of CAR T Cell Frequencies in Axicabtagene Ciloleucel and Tisagenlecleucel Patients Using Duplex Quantitative PCR
by: Maria-Luisa Schubert, et al.
Published: (2020-09-01)

Author Correction: CAR-T cell therapy-related cytokine release syndrome and therapeutic response is modulated by the gut microbiome in hematologic malignancies
by: Yongxian Hu, et al.
Published: (2024-03-01)

Monitoring CAR T cells in peripheral blood by flow cytometry following Tisagenlecleucel in Fundeni Clinical Institute, Bucharest
by: Popa Delia C., et al.
Published: (2023-07-01)

Correction: Tisagenlecleucel infusion in patients with relapsed/refractory ALL and concurrent serious infection
Published: (2021-10-01)

Melatonin as an immunomodulator in CD19-targeting CAR-T cell therapy: managing cytokine release syndrome
by: Na Zheng, et al.
Published: (2024-01-01)

Focused evaluation of the roles of macrophages in chimeric antigen receptor (CAR) T cell therapy associated cytokine release syndrome
by: Hanfei Guo, et al.
Published: (2022-03-01)

Hemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS) following treatment with tisagenlecleucel
by: Reyes Maria Martín‐Rojas, et al.
Published: (2022-01-01)

Clinically Applicable Assessment of Tisagenlecleucel CAR T Cell Treatment by Digital Droplet PCR for Copy Number Variant Assessment
by: Soragia Athina Gkazi, et al.
Published: (2022-07-01)

Severe acute heart failure during or following cytokine release syndrome after CAR T-cell therapy
by: Kyoko Yoshihara, et al.
Published: (2022-01-01)

P1398: AXICABTAGENE CILOLEUCEL VERSUS TISAGENLECLEUCEL CAR-T CELLS IN RELAPSED OR REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA
by: Nico Gagelmann, et al.
Published: (2023-08-01)

Pooled safety analysis of tisagenlecleucel in children and young adults with B cell acute lymphoblastic leukemia
by: Rajen Mody, et al.
Published: (2021-08-01)

CAR-T cell therapy-related cytokine release syndrome and therapeutic response is modulated by the gut microbiome in hematologic malignancies
by: Yongxian Hu, et al.
Published: (2022-09-01)

Correction: Signaling pathways in the regulation of cytokine release syndrome in human diseases and intervention therapy
by: Xia Li, et al.
Published: (2021-11-01)

Current approaches in the grading and management of cytokine release syndrome after chimeric antigen receptor T-cell therapy
by: Riegler LL, et al.
Published: (2019-02-01)

Early induction of cytokine release syndrome by rapidly generated CAR T cells in preclinical models
by: Arezoo Jamali, et al.
Published: (2024-03-01)

Tisagenlecleucel infusion in patients with relapsed/refractory ALL and concurrent serious infection
by: Weijie Li, et al.
Published: (2021-01-01)

Cytokine release syndrome was an independent risk factor associated with hypoalbuminemia for patients with relapsed/refractory hematological malignancies after CAR-T cell therapy
by: Shuyi Ding, et al.
Published: (2023-11-01)

Cytokine release syndrome
by: Alexander Shimabukuro-Vornhagen, et al.
Published: (2018-06-01)

Cytokine release syndrome
by: Esra Yildizhan, et al.
Published: (2018-12-01)

Neutrophil activation and clonal CAR-T re-expansion underpinning cytokine release syndrome during ciltacabtagene autoleucel therapy in multiple myeloma
by: Shuangshuang Yang, et al.
Published: (2024-01-01)

Spotlight on Tocilizumab in the Treatment of CAR-T-Cell-Induced Cytokine Release Syndrome: Clinical Evidence to Date
by: Si S, et al.
Published: (2020-08-01)

Efficacy and Safety of CAR-T Cell Products Axicabtagene Ciloleucel, Tisagenlecleucel, and Lisocabtagene Maraleucel for the Treatment of Hematologic Malignancies: A Systematic Review and Meta-Analysis
by: Jun Meng, et al.
Published: (2021-07-01)

Accurate In-Vivo Quantification of CD19 CAR-T Cells after Treatment with Axicabtagene Ciloleucel (Axi-Cel) and Tisagenlecleucel (Tisa-Cel) Using Digital PCR
by: Anita Badbaran, et al.
Published: (2020-07-01)

Rituximab and Cytokine Release Syndrome
by: Hrishikesh S. Kulkarni, et al.
Published: (2012-03-01)

Corrigendum: Efficacy and Safety of CAR-T Cell Products Axicabtagene Ciloleucel, Tisagenlecleucel, and Lisocabtagene Maraleucel for the Treatment of Hematologic Malignancies: A Systematic Review and Meta-Analysis
by: Jun Meng, et al.
Published: (2021-10-01)

Cytokine Release Syndrome After Modified CAR-NK Therapy in an Advanced Non-small Cell Lung Cancer Patient: A Case Report
by: Xiaodi Zhang, et al.
Published: (2022-05-01)

1260 Rapid cytokine release syndrome caused by short-term CAR T cells in a preclinical mouse model
by: Arezoo Jamali, et al.
Published: (2023-11-01)

Regulation of CAR T cell-mediated cytokine release syndrome-like toxicity using low molecular weight adapters
by: Yong Gu Lee, et al.
Published: (2019-06-01)

Cytokine release syndrome after radiation therapy: case report and review of the literature
by: Christopher A. Barker, et al.
Published: (2018-01-01)

Cytokine Release Syndrome: Current Perspectives
by: Murthy H, et al.
Published: (2019-10-01)

Effectiveness of tisagenlecleucel versus real-world standard of care in relapsed/refractory follicular lymphoma
by: Yanni Hao, et al.
Published: (2023-06-01)